Board of Directors
Leif Håkansson has a background as a Assoc. Professor at Lund, University, Senior Consultant in Oncology and Head of Clinical Tumorology at the University Hospital in Linköping. Leif Håkansson received both his MD and PhD at Lund University and subsequently held various positions at both university hospitals in Linköping and Lund. Dr. Håkansson’s research includes immune parameters important for immune and biochemical therapy in various forms of cancer, p. a. kidney cancer, malignant melanoma and colon cancer Leif Håkansson has published more than 75 reviewed articles, held more than 40 conference presentations on the above and other topics and is the inventor of more than 10 approved patents. Leif Håkansson is, among other responsibilities, in the board of CDDF – the Cancer Drug Development Forum.
MBA, M.Sc. Formerly C.E.O of NeuroVive Pharmaceutical AB and G.M. of Schering-Plough AB. Has 30 years of drug industry experience, with several executive positions in marketing and corporate management.
Jackie is English, and she has many years of experience in analysis and business development in the pharmaceutical industry. Today, she owns and operates a consultancy that analyzes, advises and supports pharmaceutical and biotech companies in development, partnership and sale of projects or entire companies to major pharmaceutical companies. Jackie has previously worked with CanImGuide in her consultancy role and she knows the company well.
Chris is an Englishman and has a wealth of experience from the pharmaceutical industry, from both large and smaller companies. Today, Chris is Global Operational Manager (COO) at GW Pharmaceuticals with a market capitalization of several billion USD. Chris can supply the CanImGuide Board with a name and reputation with significant market value, as well as a strong and current foundation and connections among major pharmaceutical companies.
Lars Karlsson MD, PhD, has extensive experience in drug discovery and development from senior positions at Johnson & Johnson, Regulus Therapeutics, Novo Nordisk, Silence Therapeutics, and Ferring Pharmaceuticals. He has expertise in immunology, pharmacology and translational science.